ReachMD CME

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guidelin...

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/igan-soc-strengths-and-limits/54682/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represent a major pa...

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/mechanism-based-targeting-why-april-matters-in-igan/54681/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline update...

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/april-uncovered-an-upstream-driver-in-igan/54680/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline updates represe...

CME credits: 1.00 Valid until: 10-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-4-hit-hypothesis-foundations-of-igan-pathogenesis/51035/ IgA nephropathy (IgAN) remains the most common primary glomerulonephritis worldwide and a leading cause of chronic kidney disease and end-stage kidney disease in adolescents and young adults. The 2025 KDIGO clinical practice guideline upda...

CME credits: 0.25 Valid until: 06-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/breaking-ground-2025-milestones-in-cushing-syndrome-and-looking-forward-to-2026/50059/ 2025 delivered an expanded approval for Cushing syndrome for one agent, a complete response letter for another, and deeper insights on the prevalence of Cushing syndrome (or hypercortisolism) in people with diffic...

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/So-You-Think-You-Want-a-TKI/54102/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emp...

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/Who-Needs-a-TKI-Identifying-the-Right-Candidates/54101/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current ant...

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/To-Implant-or-to-Inject/54100/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasi...

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/TKI-The-New-TKO-for-Retinal-Diseases/54099/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF thera...

CME credits: 0.75 Valid until: 04-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Struggle-Is-Real/54098/ This activity examines the evolving role of tyrosine kinase inhibitors (TKIs) in treating exudative retinal diseases such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Experts discuss limitations of current anti-VEGF therapies, emphasizin...

CME credits: 0.25 Valid until: 24-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/inside-the-igan-clinic-shared-decision-making-into-practice/26633/ Professor Jonathan Barratt illustrates the integration of shared decision-making in the management of IgA nephropathy while interacting with a real patient with IgAN, highlighting how patient-centered conversations about proteinuria,...

CME credits: 0.25 Valid until: 16-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/case-based-approach-managing-hyperkalemia-in-patients-with-ckd-and-heart-failure/37617/ Using a real-world patient case, Drs. Ellie Kelepouris and Nihar Desai examine clinical challenges in managing hyperkalemia among patients with chronic kidney disease (CKD) and heart failure (HF). They explore th...

CME credits: 0.25 Valid until: 16-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-ckd-ap-at-the-source-key-mechanisms-and-treatments/37606/ Drs. Steven Fishbane and Maurizio Gallieni discuss chronic kidney disease-associated pruritus (CKD-aP), a prevalent and under-recognized complication of CKD. They review the epidemiology, pathophysiology, and treatment strategies su...

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/safety-clinical-integration-and-the-emerging-fifth-pillar-in-hf-practice/54635/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findi...

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/evidence-at-a-glance-the-totality-of-evidence-impacting-clinical-decision-making-in-patients-with-hfref-without-a-recent-worsening-event/54634/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persis...

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/do-not-delay-timing-triggers-and-identifying-the-right-patient-for-additional-therapies-in-hfref/54633/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular...

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-why-add-more-therapies-the-clinical-rationale-for-layering-therapies-in-patients-with-hfref/54632/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognize...

CME credits: 0.75 Valid until: 13-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/when-gdmt-isnt-enough-understanding-residual-risk-in-patients-with-hfref/51036/ Patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event pose a major clinical challenge: persistent and under-recognized cardiovascular (CV) risk. Recent findi...

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/gdmt-is-working-fine-so-why-add-more-therapies-for-patients-with-hfref/48811/ Contemporary trial data and global registries consistently show that ambulatory patients with heart failure with reduced ejection fraction (HFrEF) who have not experienced a recent worsening event still carry residual risk...

CME credits: 0.25 Valid until: 10-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/targeting-b7-h3-in-es-sclc-advancing-targeted-therapy-through-evidence-based-innovation-and-multidisciplinary-care/36232/ This online educational activity reviews the scientific rationale for B7-H3 as a therapeutic target in extensive-stage small cell lung cancer (ES-SCLC). Tune in for recent clinic...

CME credits: 1.00 Valid until: 08-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/test-your-skills-and-learn-from-experts-on-best-practice-in-diagnosis-and-management-of-systemic-mastocytosis/54694/ On-demand webcast featuring expert-informed best practices for diagnosing and managing patients with systemic mastocytosis (SM) as well as the latest data on new and emerging SM thera...

CME credits: 1.00 Valid until: 05-02-2027 Claim your CME credit at https://reachmd.com/programs/cme/early-clues-lasting-impact-detecting-and-treating-alzheimers-disease-in-its-earliest-stages/56389/ Watch this webcast exploring the evolving landscape of early Alzheimer’s disease (AD) detection and treatment and highlighting the role of cognitive screening, fluid biomarkers, and emerging therapies....

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/from-late-line-rescue-to-early-line-option-the-potential-for-bispecific-antibodies-in-multiple-myeloma/49264/ This educational activity examines the growing evidence supporting bispecific antibodies in earlier treatment lines of multiple myeloma. Experts discuss the rationale for upstream use of bis...

CME credits: 0.50 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-in-hnscc-evolving-strategies-across-the-disease-continuum/48999/ This online educational activity provides clinicians with an in-depth review of the latest findings in head and neck squamous cell carcinoma (HNSCC) from ESMO 2025, highlighting advances in both resectable locally advanc...